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Background. Although patients with idiopathic dilated cardiomyopathy (DCM) have no
coronary artery disease, regional impairment of myocardial perfusion combined with pre-
served metabolism has been found using positron emission tomography (PET). Our aim was to
assess the prognostic relevance of PET-mismatch between stress myocardial perfusion and
glucose uptake on clinical outcome in DCM.
Methods. In 24 patients with DCM who underwent both myocardial perfusion and
metabolism PET scanning, ‘‘mismatch’’ was assessed and the association with clinical outcome
(hospitalization, mortality, and heart transplantation) was investigated.
Results. Mismatch was found in 16 patients (66.7%). Univariate analysis showed that the
presence of mismatch was associated with adverse outcome (P 5 0.03). After adjustment for
sex and age, the association remained signiﬁcant with an adjusted relative risk of 10.4 (95% CI
1.1-103; P 5 0.04) for death, heart transplant, or hospitalization. Univariate analysis also
showed that a higher extent of mismatch was signiﬁcantly associated with adverse outcome
(P 5 0.02). After adjusting for sex and age, the association remained signiﬁcant with an
adjusted relative risk of 6.5 [95% CI 1.2-36; P 5 0.03] for death, heart transplantation, or
hospitalization.
Conclusion. PETstressperfusion-metabolismmismatch,indicativeforischemia,isfrequently
found in DCM patients and related to a poorer outcome. (J Nucl Cardiol 2009;16:769–74.)
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In idiopathic dilated cardiomyopathy (DCM), it has
generally been assumed that myocardial ischemia does
not play a role since the coronary arteries show by
deﬁnition no signs of signiﬁcant stenoses. However,
some studies have suggested that impaired endothelial
function and perfusion abnormalities do occur in
DCM.
1,2 Regional ischemia can be investigated with
positron emission tomography (PET), looking at a mis-
match between stress myocardial perfusion and FDG
metabolism.
3 FDG is a memory marker of transient
ischemia and thus regional myocardial uptake of FDG
can be measured at least 1 hour and in some patients up
to 24 hours after stress to assess ischemia.
4,5 Using PET,
our center has demonstrated that areas of ischemia may
be present in a substantial percentage of patients with
DCM.
6 These areas were associated with high left
ventricular wall stress and a regional switch to an
anaerobic metabolism. Furthermore, long-term treat-
ment with betablockers can increase myocardial
perfusion reserve
7 and reduce stress-induced perfusion
defects.
8 Thus far, the relevance and pathophysiological
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769role of ischemia in DCM is unknown. The ischemic
regions may be the result of cardiac dysfunction. This
might be explained by a reduced cardiac output leading
to myocardial ischemia, especially during stress, which
may lead to cardiac dysfunction in a vicious circle.
Alternatively, these regions may be related to changes
associated with DCM such as endothelial dysfunction,
decreased angiogenesis, and impaired perfusion.
9 Since
PETstudiessuggest regionsofchronicischemiainDCM,
it is tempting to draw parallels with ischemic heart dis-
ease. Ischemia and hibernation in heart failure due to
coronary heart disease predict a higher mortality rate if
left untreated and shows substantial beneﬁt from revas-
cularisationtherapyintermsofprognosis.
10,11Theaimof
thisstudywastoassessthepotentialrelevanceofregional
ischemia identiﬁed by PET on clinical outcome in DCM.
METHODS
Patient Population and Study Design
Twenty-four patients with DCM were identiﬁed with both
myocardial perfusion and glucose uptake PET scans available.
The data from 22 of these patients were described in an earlier
publication of our center.
6 Underlying causes for heart failure
(e.g., hypertension, valvular disease, and diabetes) were exclu-
ded using clinical history, physical examination, blood
chemistry, echocardiography, and coronary angiography.
Additionalendomyocardialbiopsywasperformedin15patients
and did not reveal a cause for left ventricular dysfunction.
Echocardiography was used to assess left ventricular end dia-
stolic dimension (LVEDD) and left ventricular ejection fraction
(LVEF). Peak oxygen consumption (VO2max) was obtained in
22 patients (2 patients were not able to exercise adequately).
PET Study Protocol
All PET scans were performed after withdrawal of
vasoactive medications including diuretics, ACE-inhibitors,
beta-blockers, calcium-channel blockers, statins, and long
acting nitrates at least 24 hours before the PET study. PET
scans were performed on a 951 Siemens (ECAT) positron
camera (Siemens AG, Knoxﬁlle, TN), which images 31 planes
simultaneously over 10.8 cm (axial ﬁeld of view). Positioning
of the subjects was done with the aid of a rectilinear scan.
Photon attenuation was measured using an external ring source
ﬁlled with
68Ge/
68Ga and data were automatically corrected for
accidental coincidence and dead time. Patients were continu-
ously monitored with 12-lead electrocardiography and blood
pressure was obtained every 10 minutes. During pharmaco-
logically induced stress, blood pressure was measured every
minute. Myocardial perfusion was measured according to the
methods described by Schelbert et al
12 using
13NH3 as a per-
fusion tracer and dipyridamol as the pharmacological stress
agent. After injection of
13NH3 (370 MBq) dynamic rest imag-
ing was performed for 15 minutes (frames 12 9 10 seconds,
1 9 2 minutes, 1 9 4 minutes, 1 9 7 minutes). Dipyridamol
stress imaging was performed identically after dipyridamol
infusion 6 minutes prior to the injection of
13NH3. Myocardial
glucose uptake was studied according to the methods described
by Choi et al
13 using
18FDG as tracer.
18FDG was injected
20 minutes after the last
13NH3 injection. To ensure sufﬁcient
myocardial glucose uptake, patients were either given 75 g of
glucose orally or the glucose clamping technique was applied.
18FDG imaging was performed 5 minutes after injection of
18FDG (200 MBq) and continued for 35 minutes (frames
8 9 15 seconds, 4 9 30 seconds, 1 9 1m i n u t e s ,19 5m i n u t e s ,
1 9 10 minutes, 1 9 15 minutes).
Analysis of PET Data
The analysis of PET data has been extensively described
in a previous publication.
3 In brief, all data were reoriented to
10 short-axis images. Each of the 10 slices was divided into 48
segments (7.5 each). For each individual, segment myocardial
perfusion and glucose uptake were calculated. From these data,
a parametric polar map for each modality was constructed. To
calculate mismatch, we used the dipyridamol-derived perfu-
sion. Quantiﬁcation of mismatch was performed by ﬁrst
normalizing the
18FDG uptake polar map and the dipyridamol
perfusion polar map to their means. Then, a difference polar
map was created by subtracting the normalized dipyridamol
perfusion polar map from the normalized
18FDG uptake polar
map. Mismatch for each of the 480 segments was calculated as
the percentage myocardium above the 95% conﬁdence interval
(CI) of a normal data base and results were expressed as per-
centage of the total myocardium.
Follow-up
Patients were contacted by telephone and interviewed and
medical records were reviewed. The primary endpoint was
deﬁned as cardiac death, heart transplantation, or hospitaliza-
tion for progressive heart failure. Cardiac death was
ascertained by medical records. Follow-up was completed in
all 24 patients.
Statistical Analysis
Data are expressed as the mean ± standard deviation and
Student’s t-test was used to compare the means of continuous
variables. Univariate analyses of cumulative event rates for
different groups were estimated using the Kaplan-Meier
method. A multivariate analysis including sex, age and PET
mismatch between stress myocardial perfusion and glucose
uptake was performed using Cox regression techniques. Sta-
tistical analysis was performed using SPSS, version 12.0.
RESULTS
Patient Characteristics
The study population consisted of 24 patients and
their characteristics are shown in Table 1. Age was
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ejection fraction was 32 ± 14%, and mean LVEDD
was 66 ± 7 mm. Average VO2max was 21.6 ± 4.4
mL/kg/minutes.
PET Data
Resting myocardial perfusion was 106 ± 24
mL/minutes per 100 g and dipyridamol myocardial
perfusion was 186 ± 45 mL/minutes per 100 g. Total
18FDG uptake was 56 ± 18 lmol/minutes per 100
grams. Stress perfusion-metabolism mismatch was
found in 16 patients (67%), with a mean of 14% (range
4.5-32%) of the left ventricular myocardium.
Mismatch and Survival
Mean duration of follow-up was 5.5 years during
which 10 patients (42%) reached the primary endpoint;
seven patients died, two patients received heart trans-
plantation, and one patient was hospitalized for
progressive heart failure.
Clinical outcome in patients with (n = 16) vs
patients without mismatch (n = 8) was analysed and
nine events (56%) in patients with mismatch and one
event (13%) in patients without mismatch were found.
Univariate Kaplan-Meier survival analysis with log-rank
statistics showed a signiﬁcant better outcome in patients
without mismatch (P = 0.03) (Figure 1). Adjusting for
sex and age with Cox-proportional hazard showed a
hazard ratio of 10.4 (95% CI 1.1-103, P = 0.04). The
hazard ratio for age was 1.0 (95% CI 0.97-1.1, P = 0.34)
and sex 2.0 (95% CI 0.56-7.1, P = 0.29).
In order to determine whether the extent of PET
stress perfusion-metabolism mismatch inﬂuences clini-
cal outcome, patients were ranked into two groups
according to the median percentage of mismatch. In
patients below the median percentage of mismatch, two
events occurred, compared to seven events in patients
above the median value. Univariate survival analysis
showed a signiﬁcant better outcome in patients below
the median (P = 0.02) (Figure 2). Multivariate analysis
with adjustment for sex and age showed a hazard ratio of
6.5 (95% CI 1.2-36, P = 0.03). The hazard ratio for age
was 1.0 (95% CI 0.98-1.1, P = 0.34) and sex 1.5 (95%
CI 0.42-5.6, P = 0.29).
Table 1. Clinical characteristics of all patients and patients with and without mismatch measured by
PET
Total
(n 5 24)
Group 1, no mismatch
(n 5 8)
Group 2, mismatch
(n 5 16)
P, Group 1
vs 2
Clinical data
Age (years) 49 54 46 0.19
Men (%) 59 67 50 0.44
Systolic blood pressure
(mmHg)
109 110 108 0.76
Diastolic blood pressure
(mmHg)
64 66 63 0.35
Heart rate (/minutes) 74 72 75 0.65
LV function data
LVEDD* (mm) 66 64 66 0.58
LVEF** (%) 32 32 34 0.81
VO2max (mL/kg/minutes) 21 21 21 0.98
Mean values: *left ventricular end diastolic diameter, **left ventricular ejection fraction.
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Figure 1. Kaplan-Meier survival according to the presence of
mismatch.
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The present study is the ﬁrst to demonstrate an
association between myocardial PET stress perfusion-
metabolism mismatch and clinical outcome in patients
with DCM.
There is convincing evidence that in ischemic heart
disease, a deﬁcient oxygen supply as a result of coronary
artery disease is the primary cause for myocardial dys-
function, leading to cardiac remodeling and ultimately
heart failure.
14 However, the opposite may also be true as
there is increasing evidence that left ventricular dys-
function and heart failure cause coronary perfusion
abnormalities and myocardial ischemia, which may in
turn result in further myocardial dysfunction. Unverferth
et al
15 were the ﬁrst to propose possible involvement of
ischemia in the pathophysiology of DCM and since then
several studies have shown myocardial perfusion and
metabolism abnormalities in DCM. We previously dem-
onstrated that regional stress perfusion-metabolism
mismatch occurs in patients with DCM.
6 These regions
showedan additional switch from aerobic toan anaerobic
metabolism; ﬁndings comparable with chronic myocar-
dial ischemia in ischemic cardiomyopathy. These
perfusion abnormalities may have multiple explanations.
First, dilation of the ventricles results in a decrease of
capillary density, thereby increasing the distances over
which oxygen has to diffuse. A study from Abraham et al
showed a 66% decrease in capillary density in patients
with DCM.
16 This decrease in capillary density may in
part be explained by a defective angiogenesis. This fun-
damental process by which new blood vessels are formed
is characterized by a precise interplay among multiple
pro- and anti-angiogenic molecules, and at least one of
these angiogenic factors, vascular endothelial growth
factor (VEGF), was shown to be selectively down regu-
lated in DCM.
17 However, much remains unknown about
capillary and VEGF expression in DCM. Other patho-
physiological changes occurring in the failing heart that
impair myocardial perfusion include myocardial ﬁbrosis
and matrix apposition.
18 Also, arteriolar and capillary
diameter and swelling in DCM have been reported.
19
Finally, models of DCM in Syrian hamsters showed mi-
crocirculatory defects caused by microvascular spasms
and endothelial dysfunction leading to myocytolysis and
ischemia.
20
The PET stress perfusion-metabolism mismatch
characteristics seen in our population strongly resemble
ischemia of ischemic heart disease. Chronic ischemia
might also lead to hibernation, but this has not been
investigated in our patients since mismatch was assessed
between myocardial perfusion during stress and glucose
uptake directly after stress. Alternatively, alterations of
myocardial substrate metabolism may occur as a result of
heart failure without signs of ischemia. Fatty acid
metabolism in patients with DCM is regionally impaired
and a relation with prognosis has recently been found
using nuclear imaging with
123I-betamethyl-p-iodo-
phenyl-pentadecanoic acid combined with
201Tl.
21
Moreover, a study using
201Tl with single photon emis-
sion computed tomography and
18FDG PET in patients
with DCM reported mismatch areas that were related to
prognosis, which is consistent with the results of our
study.
22 Furthermore, functional impairment assessed by
dobutamine stress echocardiography in DCM suggests
hibernation; 69% of the patients with DCM show a
decrease in wall motion during induced stress.
23 These
ﬁndings are similar to ischemic contractile responses in
patients with coronary artery disease during dobutamine
stress echocardiography. Because of these similarities, it
is tempting to draw parallels between ischemic myo-
cardium in DCM and ischemic cardiomyopathy. The
pathological concept of myocardial hibernation was ﬁrst
proposed by Rahimtoola
24 to characterize a situation of
‘‘prolonged subacute or chronic ischemia in which
myocardial contractility and metabolism and ventricular
function are reduced to match the reduced blood supply
which is a new state of equilibrium whereby myocardial
necrosis is prevented, and the myocardium is capable of
restoring and returning to normal or near-normal func-
tion on restoration of an adequate blood supply.’’ In
ischemic heart disease, areas of noncontractile, but
viable myocardium are important as patients show tre-
mendous beneﬁt from cardiac revascularisation therapy
over patients without hibernating myocardium.
25 Obvi-
ously, ischemic cardiomyopathy is caused by coronary
artery disease, and restoring myocardial perfusion in
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Figure 2. Kaplan-Meier survival in patients according to the
percentage of mismatch.
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terms of coronary bypass grafting since coronaries are
normalbydeﬁnition and perfusion abnormalities occur at
the level of arterioles and capillaries.
Higher mortality in our DCM patients with PET
mismatch or chronic ischemia may, in theory, have two
explanations. First, primary myocardial dysfunction
results in myocardial remodeling, which predispose to
perfusion abnormalities.
26 The resulting ischemia fur-
ther impairs cardiac function, and so on. This suggests a
reciprocal relation between myocardial dysfunction and
ischemia, resulting in accelerated disease progression.
27
Second, multiple regional adaptive responses due to
chronic ischemia may lead to electrically unstable sub-
strate with increased risk of sudden cardiac death.
28
Thus, the higher mortality may partially be explained by
hibernating myocardium which is likely to accelerate
disease progression and is prone to develop potentially
lethal arrhythmias. Both may be present simultaneously
and might explain the observed high rate of mortality in
our patients with mismatch.
Given the relation between mismatch and prognosis
found in our study and the observed abnormalities in
microvessels in DCM, one could speculate that thera-
peutic interventions using, e.g., VEGF or erythropoietin
to stimulate vascular growth in ischemic regions
29 might
have a positive effect on prognosis for patient with heart
failure due to DCM.
30
This study has some limitations which merit con-
sideration. The study was retrospective and therefore the
results require conﬁrmation in prospective investiga-
tions. A limited number of patients was studied and
although a signiﬁcant relation could be found between
mismatch and clinical outcome, this has to be conﬁrmed
in larger patient groups. Noteworthy, in our study stan-
dard parameters like peakVO2 did not predict mortality
while perfusion-metabolism did. This might be explained
by the fact that our study was relatively small or that the
range of standard parameters in our patient groups is
limited. The fact that stress perfusion-metabolism mis-
match did predict mortality might suggest that this
parameter is more powerful than the standard parameters
that predict mortality. Parameters, like NT-proBNP, that
are now known to be of predictive value were not mea-
sured in our patients.
CONCLUSION
This study showed that in patients with DCM, PET
stress perfusion-metabolism mismatch is frequently
found and signiﬁcantly associated with clinical outcome.
Larger prospective studies are needed to conﬁrm these
results and further studies are required to investigate the
role of mismatch as a pathophysiological substrate for
cardiac dysfunction and disease progression in patients
with DCM.
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